Depressionsscreening bei Epilepsiepatienten

Metternich, Birgitta; Wagner, Kathrin; Buschmann, F.; Anger, Robin; Schulze‐Bonhage, Andreas

doi:10.1007/s10309-012-0269-z

Cited by 5 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We report the raw VAS scores alongside the EQ-5D summary index scores. The Quality of Life in Epilepsy Inventory–31 items (QOLIE-31) measures health-related QoL (HRQoL) [ 26 ], which has been deemed appropriate for individuals with TSC [ 27 ]. The QOLIE-31 features 30 items across 7 dimensions (overall QoL, seizure worry, emotional well-being, energy/fatigue, cognitive function, medication effects, and social functioning) and a separate VAS analogous to the VAS in the EQ-5D.…”

Section: Methodsmentioning

confidence: 99%

“…The NDDI-E features 6 four-level Likert items regarding the frequency of common depressive symptoms, such as feeling guilty, frustrated, or weary of life. An aggregate value of ≥14 points (range: 6–24 points) is indicative of depressive mood in the validated German version [ 27 ]. The Epilepsy Stigma Scale measures disease-related stigma [ 28 ], using three questions (‘I feel that some people are uncomfortable with me’, ‘I feel some people treat me like an inferior person,’ and ‘I feel some people would prefer to avoid me’).…”

Section: Methodsmentioning

confidence: 99%

“… The Epilepsy Stigma Scale measures disease-related stigma [ 28 ], using three questions (‘I feel that some people are uncomfortable with me’, ‘I feel some people treat me like an inferior person,’ and ‘I feel some people would prefer to avoid me’). An affirmative answer to any question indicates stigma, with an aggregate value of 3 suggesting a severe stigma [ 27 ]. We dichotomised the Epilepsy Stigma Scale into ‘severe stigma’ and ‘no or not severe stigma’, according to Baker et al [ 27 ].…”

Section: Methodsmentioning

confidence: 99%

“…An affirmative answer to any question indicates stigma, with an aggregate value of 3 suggesting a severe stigma [ 27 ]. We dichotomised the Epilepsy Stigma Scale into ‘severe stigma’ and ‘no or not severe stigma’, according to Baker et al [ 27 ]. We measured therapy-related adverse events with the Liverpool Adverse Events Profile (LAEP) inventory, which features 20 four-level Likert items using summarised item values (range 20–80).…”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

Quality of life and its predictors in adults with tuberous sclerosis complex (TSC): a multicentre cohort study from Germany

Zöllner

Conradi

Sauter

et al. 2021

Neurol. Res. Pract.

View full text Add to dashboard Cite

Background Tuberous sclerosis complex (TSC) is a monogenetic, multisystemic disease characterised by the formation of benign tumours that can affect almost all organs, caused by pathogenic variations in TSC1 or TSC2. In this multicentre study from Germany, we investigated the influence of sociodemographic, clinical, and therapeutic factors on quality of life (QoL) among individuals with TSC. Methods We assessed sociodemographic and clinical characteristics and QoL among adults with TSC throughout Germany using a validated, three-month, retrospective questionnaire. We examined predictors of health-related QoL (HRQoL) using multiple linear regression analysis and compared the QoL among patients with TSC with QoL among patients with other chronic neurological disorders. Results We enrolled 121 adults with TSC (mean age: 31.0 ± 10.5 years; range: 18–61 years, 45.5% [n = 55] women). Unemployment, a higher grade of disability, a higher number of organ manifestations, the presence of neuropsychiatric manifestations or active epilepsy, and a higher burden of therapy-related adverse events were associated with worse QoL, as measured by two QoL instruments (EuroQoL-5 dimensions [EQ-5D] and Quality of Life in Epilepsy Patients [QOLIE-31]). Neuropsychiatric and structural nervous system manifestations, the number of affected organs, and therapy-related adverse events were also associated with higher depression, as measured by the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E). In multiple regression analysis, more severe therapy-related adverse events (large effect, p < 0.001), active epilepsy (large effect, p < 0.001), and neuropsychiatric manifestations (medium effect, p = 0.003) were independently associated with worse HRQoL, explaining 65% of the variance (p < 0.001). The HRQoL among patients with active TSC-associated epilepsy was worse than that among patients with drug-refractory mesial temporal lobe epilepsy (p < 0.001), and the generic QoL among patients with more than three TSC organ manifestations was similar to those of patients with severe migraine and uncontrolled asthma. Conclusions Active epilepsy, neuropsychiatric manifestations (such as anxiety and depression), and therapy-related adverse events are important independent predictors of worse quality of life among adults with TSC. Generic quality of life in TSC with several manifestations is similar to uncontrolled severe chronic diseases and significantly negatively correlates with TSC severity. Trial registration DRKS, DRKS00016045. Registered 01 March 2019.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Quality of life and its predictors in adults with tuberous sclerosis complex (TSC): a multicentre cohort study from Germany

Zöllner

Conradi

Sauter

et al. 2021

Neurol. Res. Pract.

View full text Add to dashboard Cite

show abstract

Epilepsiebehandlung

Schulze‐Bonhage

Coenen²

2013

Nervenarzt

View full text Add to dashboard Cite

The efficacy of electrical stimulation in the treatment of epileptic seizures was demonstrated experimentally even in the 1970s. Clinical studies have proven the efficacy of vagus nerve stimulation and in recent years also of stimulation of the trigeminal nerve, the anterior nucleus of the thalamus and of the epileptic focus in treating focal epilepsy. Mechanisms of action depend on the stimulation site and parameters and include activation of endogenous antiepileptic nuclei, modulation of propagation of epileptic activity and suppression of ictal activity at the site of generation. Based on available data the tolerability of peripheral and central brain stimulation appears to be good but experiences from wider clinical use are still lacking.

show abstract

Schnelle Erkennung einer depressiven Störung bei Menschen mit Epilepsie

Brandt¹,

Labudda²,

Illies³

et al. 2014

Nervenarzt

View full text Add to dashboard Cite

The prevalence of psychiatric disorders in people with epilepsy is high. Depression and anxiety disorders are especially frequent. These comorbid disorders are, however, easily overlooked. The neurological disorders depression inventory for epilepsy (NDDI-E) was developed and validated as a screening instrument with six questions. The aim of the present study was to validate a German version of the NDDI-E. After translation into German and back translation into English, the NDDI-E was presented to 144 patients at the Bethel Epilepsy Center. The Beck depression inventory II (BDI-II), the revised symptom check list by Derogatis (SCL-90-R) and the state-trait anxiety inventory (STAI) were also used. The patients were examined using the mini international neuropsychiatric interview plus (MINI Plus). The German version of the NDDI-E proved to be valid, internally consistent and easy to use.

show abstract

Depressionsscreening bei Epilepsiepatienten

Cited by 5 publications

References 27 publications

Quality of life and its predictors in adults with tuberous sclerosis complex (TSC): a multicentre cohort study from Germany

Quality of life and its predictors in adults with tuberous sclerosis complex (TSC): a multicentre cohort study from Germany

Epilepsiebehandlung

Schnelle Erkennung einer depressiven Störung bei Menschen mit Epilepsie

Contact Info

Product

Resources

About